Magnetic nanoparticles composed of ferrite (e.g., Fe3O4 and Fe2O3) have been suggested for use in delivering drugs or physiologically active materials. However, the use of magnetic nanoparticles in the medical field relies on maintaining a physiologically active material within the nanoparticles and selective delivery to an intended site (targeting capability).
Dartmouth scientists have now developed a drug delivery composition or system composed of liposome-encapsulated magnetic nanoparticles. Compositions can include either a single nanoparticle containing an active therapeutic agent or two liposome-encapsulated magnetic nanoparticles: one nanoparticle containing a therapeutic prodrug and the other nanoparticle containing an activator of the prodrug. The lipid membrane is inherently biocompatible and exhibits enhanced affinity to tissue, and specifically, directionality to hydrophobic tissue. When an alternating magnetic field (AMF) is applied to the liposome-encapsulated magnetic nanoparticles, either heat or mechanical action of the AMF on the liposome-encapsulated magnetic nanoparticles ruptures the lipid bilayer and releases the therapeutic agent, or prodrug and activator so that drug of interest is delivered locally to targeted cells. The liposome-encapsulated magnetic nanoparticles are of particular use in providing a therapeutic agent to patients with cancer.
These findings are claimed in the published PCT Patent Application No. PCT/US2011/062769. We are seeking an industrial partner to further refine and market this technology. (Ref:J614)
Last Updated: 11/12/12